Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Average (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Equity Average data on record, last reported at $51.4 million in Q3 2025.

  • For Q3 2025, Equity Average rose 68.49% year-over-year to $51.4 million; the TTM value through Sep 2025 reached $51.4 million, up 68.49%, while the annual FY2024 figure was $38.4 million, 234.86% up from the prior year.
  • Equity Average reached $51.4 million in Q3 2025 per PLX's latest filing, up from $47.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $51.4 million in Q3 2025 and bottomed at -$11.1 million in Q4 2022.
  • Average Equity Average over 5 years is $17.2 million, with a median of $20.0 million recorded in 2023.
  • Peak YoY movement for Equity Average: crashed 627.95% in 2022, then soared 757.76% in 2024.
  • A 5-year view of Equity Average shows it stood at -$2.9 million in 2021, then plummeted by 280.46% to -$11.1 million in 2022, then soared by 424.17% to $35.9 million in 2023, then rose by 5.34% to $37.8 million in 2024, then soared by 35.91% to $51.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $51.4 million in Q3 2025, $47.6 million in Q2 2025, and $44.2 million in Q1 2025.